Interleukin 12 stimulates IFN-γ-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8700-8709

  Cao, Xuefang ^a   Leonard, Karen ^a   Collins, Lynne I ^b   Cai, Sheng F ^c   Mayer, Joshua C ^c   Payton, Jacqueline E ^c   Walter, Michael J ^c   Piwnica Worms, David ^b   Schreiber, Robert D ^c   Ley, Timothy J ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR CELL;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, TRANSGENIC; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 72249083705     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1145     Document Type: Article

References (45)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor á-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155: 1151-1164
3. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562 (Pubitemid 38680433)
4. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006;16:115-123 (Pubitemid 43172060)
5. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-344
6. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-296 (Pubitemid 46697910)
7. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
8. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174
9. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006;66:7301-7309 (Pubitemid 44197712)
10. Nishikawa H, Kato T, Tawara I, et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 2005;102:9253-9257 (Pubitemid 40923550)
11. Zhou G, Drake CG, Levitsky HI. Amplification of tumor- specific regulatory T cells following therapeutic cancer vaccines. Blood 2006;107:628-636 (Pubitemid 43076387)
12. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol 2006;7:401-410
13. Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004;21:267-277 (Pubitemid 39094055)
14. Jaeckel E, von Boehmer H, Manns MP. Antigenspecific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005;54:306-310
15. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455-1465
16. Nishikawa H, Kato T, Tawara I, et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 2005;201:681-686 (Pubitemid 40395113)
17. Bushell A, Jones E, Gallimore A, Wood K. The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J Immunol 2005;174:3290-3297 (Pubitemid 40354032)
18. Tanchot C, Vasseur F, Pontoux C, Garcia C, Sarukhan A. Immune regulation by self-reactive T cells is antigen specific. J Immunol 2004;172:4285-4291 (Pubitemid 38375242)
19. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004;78:2454-2459 (Pubitemid 38228938)
20. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-1151 (Pubitemid 41541792)
21. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004;34:366-376
22. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008;28:100-111
23. Burchill MA, Yang J, Vang KB, et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 2008;28: 112-121
24. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007;27: 635-646 (Pubitemid 47628832)
25. Russell TD, Yan Q, Fan G, et al. IL-12 p40 homodimerdependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor β 1. J Immunol 2003;171:6866-6874 (Pubitemid 37532122)
26. Pollock JL, Lane AA, Schrimpf K, Ley TJ. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica 2005;90:1042-1049 (Pubitemid 41323503)
27. Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ. Mouse models of acute promyelocytic leukemia. Curr Opin Hematol 2001;8:206-211 (Pubitemid 32762962)
28. Gross S, Piwnica-Worms D. Real-time imaging of ligand- induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607-614 (Pubitemid 41086852)
29. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6: 345-352 (Pubitemid 41716771)
30. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme Bdependent, perforin-independent mechanism. J Immunol 2005;174:1783-1786 (Pubitemid 40223916)
31. Bruder D, Probst-Kepper M, Westendorf AM, et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623-630 (Pubitemid 39255909)
32. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GMCSF- secreting cancer immunotherapy. Clin Cancer Res 2006;12:6808-6816 (Pubitemid 44876851)
33. Kilinc MO, Aulakh KS, Nair RE, et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006;177:6962-6973
34. Nishikawa H, Kato T, Tawara I, et al. IFN- γ controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005; 175:4433-4440 (Pubitemid 41361979)
35. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146 (Pubitemid 37328691)
36. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003; 14:361-368 (Pubitemid 37099449)
37. Yu XZ, Zhu L, Davis JE, Tso JY, Hansen JA, Anasetti C. Induction of apoptosis by anti-CD3 ε F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide. J Immunol 1996;157:3420-3429 (Pubitemid 126449154)
38. Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci U S A 1993;90: 2189-2193 (Pubitemid 23078591)
39. Vivo C, Levy F, Pilatte Y, et al. Control of cell cycle progression in human mesothelioma cells treated with γ interferon. Oncogene 2001;20:1085-1093 (Pubitemid 32238857)
40. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336
41. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995;270:908.
42. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995;181:901-914
43. Younes A, Pro B, Robertson MJ, et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004;10:5432-5438 (Pubitemid 39100480)
44. Ansell SM, Geyer SM, Maurer MJ, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 2006;12:6056-6063 (Pubitemid 44703769)
45. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin- 12: biological properties and clinical application. Clin Cancer Res 2007;13:4677-4685 (Pubitemid 47294773)